Neostigmine: Nursing Drug Guide, Cholinergic Crisis & NCLEX Review
Perioperative neostigmine reverses nondepolarizing neuromuscular block—but the highest-stakes errors are giving it before train-of-four (TOF) recovery, omitting or delaying the paired anticholinergic (atropine or glycopyrrolate), or treating worsening weakness with another dose when the patient is in cholinergic crisis instead of residual block.
Give atropine or glycopyrrolate before or with neostigmine to lessen bradycardia. Do not administer until the first TOF twitch is at least 10% of baseline. Overdose or dosing when blockade is nearly gone can cause cholinergic crisis (extreme weakness, secretions, bradycardia)—this requires withdrawing anticholinesterase drugs and giving atropine, not more neostigmine. In myasthenia gravis, cholinergic crisis mimics myasthenic crisis; treatment differs radically.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Confirm TOF twitch ≥10% of baseline, give weight-based neostigmine (max 0.07 mg/kg or 5 mg, whichever is less) with atropine or glycopyrrolate in separate syringes, and monitor ventilation until the patient maintains a patent airway and adequate respiratory effort. If weakness worsens after dosing, suspect cholinergic crisis—hold further anticholinesterase drugs and escalate per prescriber/anesthesia protocol, not “another reversal dose.”
Most common brand names
Neostigmine methylsulfate injection is supplied generically for intravenous use (e.g., prefilled syringes 3 mg per 3 mL [1 mg/mL] per Fresenius Kabi labeling). Institutional product strengths and packaging may vary.
Active moiety: Neostigmine (as neostigmine methylsulfate). Not interchangeable with: edrophonium, pyridostigmine, or physostigmine for reversal orders—confirm the MAR drug name and indication before administration.
Why we give it — Indications
Neostigmine methylsulfate is a cholinesterase inhibitor indicated for reversal of nondepolarizing neuromuscular blocking agents (NMBAs) after surgery. Nurses in PACU, ICU, and OR recovery coordinate with anesthesia on timing, TOF criteria, and paired anticholinergic dosing.
| Use | Detail |
|---|---|
| Reversal of nondepolarizing NMBAs | After surgery when peripheral nerve stimulation shows adequate spontaneous recovery (first TOF twitch ≥10% of pre-block baseline) and ventilation is supported until full recovery |
| Shorter-acting NMBA (e.g., rocuronium) | Labeling: lower dose (e.g., <0.04 mg/kg) when first twitch is substantially >10% of baseline or a second twitch is present |
| Longer-acting NMBA | Labeling: 0.07 mg/kg when first twitch is close to 10% of baseline or more rapid recovery is needed—verify which NMBA was used on the medication reconciliation and anesthesia record |
On a small screen, swipe or scroll sideways to see the full table.
Oral neostigmine for myasthenia gravis uses different products and dosing—not covered by the IV reversal labeling reviewed here. Follow the patient’s neurology regimen when applicable.
How it works
Neostigmine competitively inhibits acetylcholinesterase, increasing acetylcholine at the neuromuscular junction to compete with nondepolarizing NMBAs and restore neuromuscular transmission. It also has direct postsynaptic cholinomimetic effects at muscarinic sites—hence bradycardia, secretions, and GI effects unless an anticholinergic (atropine or glycopyrrolate) is co-administered per labeling.
Dosing overview
Administer only by trained providers familiar with NMBAs and reversal agents. Patient must be well ventilated with a patent airway until normal ventilation is restored. Use a peripheral nerve stimulator with train-of-four (TOF) stimulus before dosing and to guide additional boluses.
Paired anticholinergic (mandatory per labeling)
Give atropine sulfate ~15 mcg/kg or glycopyrrolate ~10 mcg/kg IV several minutes before or concomitantly with neostigmine using separate syringes. For bradycardic patients, administer the anticholinergic before neostigmine.
Pediatrics
Adult guidelines apply; pediatric patients require similar mg/kg doses (0.03–0.07 mg/kg, max 0.07 mg/kg or 5 mg total, whichever is lower). Infants and small children may be at greater risk of incomplete reversal due to decreased respiratory reserve—labeling states risks of incomplete reversal outweigh concerns about giving doses up to the maximum.
Renal / hepatic impairment
No routine dose adjustment in labeling, but elimination half-life is prolonged in anephric patients and concentration may increase with hepatic impairment—monitor longer and avoid assuming one dose fits all recovery trajectories.
Missed dose: Not applicable to scheduled home dosing for IV reversal—document each bolus, TOF data, anticholinergic given, and respiratory assessment after every administration.
Before you give it — Safety check
Pretreatment checks
- Confirm trained anesthesia/provider order; verify patient weight for mg/kg calculation
- TOF: first twitch ≥10% of pre-NMBA baseline before neostigmine; document stimulation site and counts
- Patent airway, adequate ventilation support, suction and emergency equipment available
- Anticholinergic (atropine or glycopyrrolate) prepared in a separate syringe at ordered dose
- Review NMBA used intraoperatively (rocuronium vs longer-acting agents) and time since last paralytic dose
Contraindications
- Known hypersensitivity to neostigmine methylsulfate (labeling reports urticaria, angioedema, rash, hypotension, bronchospasm, bradycardia, anaphylaxis)
- Peritonitis
- Mechanical obstruction of urinary or intestinal tracts
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Succinylcholine (depolarizing relaxant) | Labeling: not recommended to reverse—may prolong phase-1 block | Do not administer neostigmine for succinylcholine reversal; clarify orders with anesthesia |
| Certain aminoglycosides (neomycin, streptomycin, kanamycin) | Nondepolarizing neuromuscular blocking action—may require neostigmine dose adjustment to reverse block | Coordinate with pharmacy/anesthesia; extend monitoring if antibiotics continued post-op |
| Hepatic enzyme inducers/inhibitors | Pharmacokinetic interaction with neostigmine not studied; concentration may change | Monitor recovery duration longer when interacting drugs are present |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous bolus only (labeling: do not dilute for IV push; single-dose prefilled syringe—do not re-sterilize).
- Inspect solution for particulate matter and discoloration before administration
- Administer neostigmine IV bolus; maintain pressure on plunger rod during entire injection per product instructions
- Give anticholinergic IV in separate syringe before or with neostigmine per order
- Follow high-alert medication administration double-checks for mg/kg math and maximum 5 mg cap
Labeling states TOF monitoring alone should not determine adequacy of reversal—also judge patent airway, adequacy of ventilation, and skeletal muscle tone. Continue monitoring until full recovery based on patient status and NMBA/neostigmine pharmacokinetics.
Expected therapeutic response
- Improving TOF count (e.g., four twitches) and stronger voluntary muscle effort over time
- Adequate tidal volume, cough, and head lift per institutional criteria
- Stable or improved heart rate after anticholinergic co-administration
- Ability to maintain patent airway and spontaneous ventilation without escalating support
Red flags — Stop and act
Escalate immediately when reversal therapy may be causing harm rather than treating residual block.
- Increasing muscle weakness, inability to lift head, or shallow respirations after neostigmine—suspect cholinergic crisis or overdose; hold anticholinesterase drugs and notify anesthesia/prescriber
- Bradypnea, apnea, or difficulty breathing with copious oral/bronchial secretions
- Symptomatic bradycardia or hypotension despite anticholinergic pairing—continuous cardiac monitoring per labeling in cardiac disease
- Anaphylaxis signs (urticaria, angioedema, bronchospasm, cardiovascular collapse) after dose
- No meaningful improvement in neuromuscular function after appropriate dose—evaluate residual block vs crisis vs other causes; do not repeat blindly
Adverse effects
Most reactions reflect exaggerated muscarinic and nicotinic effects. Anticholinergic co-administration prevents or mitigates many muscarinic events per labeling.
| Adverse effect | Notes | Nursing response |
|---|---|---|
| Bradycardia | Most common per highlights; mitigated by atropine/glycopyrrolate | Ensure anticholinergic given; monitor HR/ECG; escalate if symptomatic |
| Nausea / vomiting | Common; muscarinic | Aspiration precautions; antiemetic per order if persistent |
| Increased secretions, bronchospasm, respiratory depression | Can progress to respiratory arrest post-marketing | Suction airway; support ventilation; emergency response |
| Hypotension, arrhythmias, syncope | Cardiovascular complications reported | Continuous monitoring in cardiac disease; notify prescriber |
| Diarrhea, increased peristalsis | GI muscarinic effects | Monitor hydration; differentiate from surgical complications |
| Diaphoresis, flushing, rash | Allergic and autonomic symptoms | Stop drug if hypersensitivity; treat anaphylaxis if present |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdosage may cause cholinesterase inhibitor toxicity or cholinergic crisis—increasing muscle weakness that can involve respiratory muscles and be fatal if untreated. This presentation can resemble myasthenic crisis; differentiation is critical because treatment differs.
Muscarinic overdose signs
- Nausea, vomiting, diarrhea, diaphoresis, increased bronchial and salivary secretions, bradycardia
- May be managed with additional atropine or glycopyrrolate per prescriber—monitor for iatrogenic anticholinergic excess
Cholinergic crisis management (labeling)
- Immediate withdrawal of all anticholinesterase medication
- Immediate atropine as recommended in labeling
- Assist ventilation if respiration is severely depressed until spontaneous breathing adequate
- Cardiac monitoring during treatment
Labeling notes edrophonium chloride may help distinguish cholinergic from myasthenic crisis in specialist settings—follow neurology/anesthesia protocol; do not increase neostigmine during cholinergic crisis.
Contact anesthesia, prescriber, and local emergency guidance per facility protocol. Ensure resuscitation equipment and anaphylaxis treatments are available before every reversal dose.
Look-alike / sound-alike and error prevention
- Neostigmine vs physostigmine vs pyridostigmine—different indications and toxicity profiles; read full drug name on syringe
- Neostigmine vs edrophonium—distinct reversal agents; verify MAR during neuromuscular monitoring
- mg/kg vs total mg cap—a 100 kg patient’s 0.07 mg/kg (7 mg) exceeds the 5 mg maximum; calculate both limits
- Neostigmine without anticholinergic—pairing omission is a high-risk administration error
- Reversal when TOF <10%—giving neostigmine too early increases neuromuscular dysfunction risk per labeling
- “Still weak—give more reversal”—escalating weakness after dose may mean cholinergic crisis; do not auto-repeat
High-risk populations
| Population | Considerations |
|---|---|
| Cardiac disease / recent ACS / arrhythmias | Labeling: increased risk of BP and HR complications; continuous BP and ECG monitoring during initiation and until stable |
| Myasthenia gravis | Increased cardiovascular risk; cholinergic vs myasthenic crisis confusion—coordinate with neurology/anesthesia |
| Pediatrics / neonates | Faster recovery with smaller cholinesterase inhibitor doses but greater risk from incomplete reversal—monitor respiratory reserve closely |
| Renal impairment | Prolonged elimination half-life in anephric patients—extend monitoring; no labeled dose change |
| Hepatic impairment | Hepatic metabolism—concentration may increase; monitor longer if hepatically cleared NMBAs were used |
| Pregnancy | No adequate human studies; animal data limited. Anticholinesterase drugs may cause uterine irritability and induce premature labor near term—use only if clearly needed. |
| Lactation | Not known if excreted in human milk; potential for serious adverse reactions in nursing infants—decision to discontinue nursing or drug per labeling, weighing importance of drug to mother. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- TOF responses and clinical strength (head lift, hand grip, tidal volume) until sustained recovery
- Respiratory rate, depth, SpO2, need for supplemental oxygen or assisted ventilation
- Heart rate, blood pressure, and ECG in patients with cardiac disease per labeling
- Secretions, bronchospasm, and level of consciousness
Document
- Weight-based neostigmine dose (mg and mg/kg), anticholinergic name/dose/time, and route
- Pre-dose TOF (≥10% first twitch), NMBA used, time of administration, and post-dose recovery trend
- Respiratory assessments aligned with extubation/PACU criteria and prescriber orders
Patient teaching
- Explain that neostigmine was given to reverse anesthesia-related muscle relaxation and restore your own breathing strength
- Report sudden worsening weakness, trouble breathing, chest tightness, severe nausea, or slow heartbeat immediately
- Follow nurse instructions before attempting to eat or drink—swallowing strength must be adequate to reduce aspiration risk
- IV reversal agents are managed by the surgical team; patients do not self-administer this medication at home
- Breastfeeding patients: discuss infant feeding plans with the care team when labeling advises weighing drug benefit against infant risk
The Hold Rule
Do not give and contact anesthesia/prescriber/pharmacist when:
- Known neostigmine hypersensitivity or active reaction (rash, bronchospasm, anaphylaxis)
- Peritonitis or mechanical urinary/intestinal obstruction (contraindicated)
- First TOF twitch <10% of baseline or no qualified peripheral nerve stimulator assessment
- Anticholinergic (atropine or glycopyrrolate) not available or not ordered to accompany neostigmine
- Calculated dose exceeds 0.07 mg/kg or 5 mg total maximum, or order is for succinylcholine reversal
- Worsening weakness after prior neostigmine dose—hold further anticholinesterase drugs until cholinergic crisis is ruled out
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Dilution | Labeling: do not dilute for IV push; use product as supplied in prefilled syringe |
| Syringe technique | Anticholinergic and neostigmine in separate syringes; maintain plunger pressure during injection |
| Storage | USP controlled room temperature 20–25°C (68–77°F) per labeling; discard unused portion |
| Commonly missed | 5 mg cap on heavy patients; repeating dose when weakness is increasing; TOF checked without documenting baseline comparison |
| Ask anesthesia when | Unclear NMBA timing, borderline TOF, need for additional bolus, or suspected cholinergic crisis |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
Neostigmine is a brief IV event with prolonged consequences if paired drugs, TOF criteria, or crisis recognition are wrong. Build reversal safety into PACU handoff the same way you would for opioids or heparin—verify weight, cap, and anticholinergic before the bolus leaves your hands.
1. Check-before-you-give protocol
- Right patient, weight, drug, dose (mg/kg and 5 mg cap), route, time—and right anticholinergic pairing
- TOF first twitch ≥10% of documented baseline; anesthesia agrees reversal is indicated
- Airway equipment, suction, and oxygen ready; assign nurse to watch ventilation during and after bolus
- Independent double-check mg/kg math on every pediatric and adult dose
2. High-alert and safety badge
Perioperative high-risk reversal agent — use double-checksNot a traditional inpatient high-alert list entry everywhere, but labeling emphasizes trained providers, TOF criteria, anticholinergic pairing, and cholinergic crisis risk. Treat as a time-critical medication with anesthesia co-management.
3. Clinical workflow: hold and question rules
- If weakness worsens after neostigmine, stop anticholinesterase repeats and activate anesthesia—consider cholinergic crisis pathway
- If HR drops despite anticholinergic, prepare additional atropine per protocol and continuous monitoring
- Do not extubate or downgrade respiratory monitoring based on TOF alone—confirm clinical ventilation and muscle tone
4. Critical teach-back questions
- “What symptoms should you report right away after surgery?” (Patient should name worsening weakness, breathing trouble, choking on secretions, severe nausea, or dizziness.)
- “When will staff clear you to eat?” (Patient should say they must wait until swallowing and alertness meet nurse/SLP criteria—not as soon as they feel hungry.)
5. Care coordination
Anesthesia / surgeon: Orders reversal timing, additional boluses, and response to inadequate recovery or crisis
Pharmacist: Dose verification, NMBA interaction review, and antibiotic-related block prolongation
🧠 Quick mental checklist
- Is first TOF twitch at least 10% of baseline?
- Is atropine or glycopyrrolate ready in a separate syringe?
- Does mg/kg dose respect the 5 mg total cap?
- Is weakness improving—not worsening—after the bolus?
- Are airway, ventilation, and cardiac monitoring adequate for the next hour?
Neostigmine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for neostigmine using a tabbed PACU reversal case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, post-dose trend interpretation, documentation cloze, repeat-dose judgment, and a matrix urgency item—recognise cues → analyse block recovery → prioritise → act → evaluate outcomes (ventilation and TOF trends vs cholinergic crisis).
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Neostigmine methylsulfate 3.5 mg IV once (0.05 mg/kg for 70 kg) — due now per anesthesia
- Glycopyrrolate 0.7 mg IV — give before or with neostigmine (separate syringe)
- Rocuronium given intra-op; last paralytic dose 45 minutes ago
- Ondansetron 4 mg IV PRN nausea
- Potassium 3.9 mEq/L; magnesium 2.0 mg/dL; glucose 112 mg/dL
- Creatinine 0.8 mg/dL (baseline)
- 12-lead ECG: sinus rhythm, no acute ischemic changes
- 1015: HR 58, BP 118/72, RR 10 shallow, SpO2 94% on 6 L/min simple mask
- Urine output 120 mL since OR exit
- TOF at ulnar nerve: 2 of 4 twitches; first twitch ~15% of pre-block baseline per anesthesia note
- 1010: Patient opens eyes to voice; cannot sustain head lift >5 seconds
- 1012: Copious oral secretions suctioned; breath sounds rhonchi bilaterally
- 1014: Anesthesia at bedside; orders reversal when TOF criteria met—anticholinergic must not be skipped
Answer key & rationale
Frequently asked questions
Why must atropine or glycopyrrolate be given with neostigmine?
Neostigmine increases acetylcholine at muscarinic receptors, causing bradycardia and other muscarinic effects. Labeling requires atropine (~15 mcg/kg) or glycopyrrolate (~10 mcg/kg) IV before or with neostigmine in separate syringes to lessen bradycardia.
When should a nurse hold neostigmine?
Hold for hypersensitivity, peritonitis, mechanical urinary or intestinal obstruction, TOF first twitch below 10% of baseline, missing anticholinergic pairing, dose over 0.07 mg/kg or 5 mg total, succinylcholine reversal orders, or worsening weakness after a prior dose.
What is cholinergic crisis?
Overdose can cause extreme muscle weakness involving respiratory muscles. Treatment is withdrawal of anticholinesterase drugs and immediate atropine with ventilatory support—not additional neostigmine.
What TOF level is required before dosing?
First TOF twitch must be at least 10% of the pre-neuromuscular blocker baseline. Clinical assessment of airway, ventilation, and muscle tone is still required.
What is the maximum neostigmine reversal dose?
0.07 mg/kg or 5 mg total, whichever is less, within the adult range of 0.03–0.07 mg/kg IV.
References
- U.S. National Library of Medicine. NEOSTIGMINE METHYLSULFATE injection — Full prescribing information. DailyMed (NDA 203629; Fresenius Kabi USA, LLC).https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0b509c3-8dc8-48cc-b7a8-16b93ad706c6&type=display
- Drugs and Lactation Database (LactMed). Neostigmine. Bethesda (MD): National Institute of Child Health and Human Development; updated December 21, 2020.https://www.ncbi.nlm.nih.gov/books/NBK501379/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.